Tasisulam (LY573636) is primarily explored for its potential in cancer therapy, particularly as an anticancer agent. It functions by inducing apoptosis in cancer cells, making it a candidate for treating various types of tumors. The compound has been studied in clinical trials for its efficacy against solid tumors, including melanoma, ovarian cancer, and non-small cell lung cancer. Its mechanism involves disrupting cell cycle progression and promoting cell death, which may offer a therapeutic advantage in resistant or aggressive cancers. Research continues to evaluate its safety, dosing, and effectiveness in combination with other treatments.